Example of Clinical and Applied Thrombosis/Hemostasis format
Recent searches

Example of Clinical and Applied Thrombosis/Hemostasis format Example of Clinical and Applied Thrombosis/Hemostasis format Example of Clinical and Applied Thrombosis/Hemostasis format Example of Clinical and Applied Thrombosis/Hemostasis format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Clinical and Applied Thrombosis/Hemostasis format Example of Clinical and Applied Thrombosis/Hemostasis format Example of Clinical and Applied Thrombosis/Hemostasis format Example of Clinical and Applied Thrombosis/Hemostasis format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Clinical and Applied Thrombosis/Hemostasis — Template for authors

Publisher: SAGE
Categories Rank Trend in last 3 yrs
Hematology #64 of 123 down down by 9 ranks
journal-quality-icon Journal quality:
Medium
calendar-icon Last 4 years overview: 614 Published Papers | 1963 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 29/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access

Springer

Quality:  
High
CiteRatio: 4.6
SJR: 1.06
SNIP: 1.301
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.3
SJR: 1.037
SNIP: 0.989
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 7.2
SJR: 1.638
SNIP: 0.997

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

1.374

26% from 2018

Impact factor for Clinical and Applied Thrombosis/Hemostasis from 2016 - 2019
Year Value
2019 1.374
2018 1.846
2017 1.852
2016 2.096
graph view Graph view
table view Table view

3.2

14% from 2019

CiteRatio for Clinical and Applied Thrombosis/Hemostasis from 2016 - 2020
Year Value
2020 3.2
2019 2.8
2018 2.5
2017 3.6
2016 3.3
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 26% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 14% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.643

30% from 2019

SJR for Clinical and Applied Thrombosis/Hemostasis from 2016 - 2020
Year Value
2020 0.643
2019 0.495
2018 0.452
2017 0.49
2016 0.533
graph view Graph view
table view Table view

1.08

59% from 2019

SNIP for Clinical and Applied Thrombosis/Hemostasis from 2016 - 2020
Year Value
2020 1.08
2019 0.68
2018 0.728
2017 0.737
2016 0.723
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 30% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 59% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Clinical and Applied Thrombosis/Hemostasis

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

SAGE

Clinical and Applied Thrombosis/Hemostasis

Clinical and Applied Thrombosis/Hemostasis is dedicated to serving as a forum for studies regarding the etiology, pathophysiology, clinical diagnosis, laboratory diagnosis, and treatment of thrombohemorrhagic disorders. Articles dealing with new diagnostic procedures are encou...... Read More

Medicine

i
Last updated on
29 Jun 2020
i
ISSN
1076-0296
i
Impact Factor
Medium - 0.663
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SageV
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M and Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 1982; 25(7): 4515–4532. URL 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1177/1076029606293692
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Steven R. Deitcher1, Craig M. Kessler2, Geno J. Merli3, James R. Rigas4, Roger M. Lyons, Jawed Fareed5

Abstract:

This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in secondary prevention of venous thromboembolic events in adults with active malignancy. Cancer patients (n = 122) with acute symptomatic venous thromboembolic events were randomly allocated to receive subcutaneous enoxaparin 1.0 mg/kg every... This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in secondary prevention of venous thromboembolic events in adults with active malignancy. Cancer patients (n = 122) with acute symptomatic venous thromboembolic events were randomly allocated to receive subcutaneous enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily (group 1a) or 1.5 mg/kg daily (group 1b) for 175 days, or subcutaneous enoxaparin 1.0 mg/kg every 12 hours for at least 5 days and until a stable international normalized ratio of 2 to 3 was achieved on oral warfarin begun on day 2 and continued to day 180 (group 2). There were no significant differences in major and minor bleeding rates between treatment groups. No bleeding events were intracranial or fatal. Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy. read more read less

Topics:

Warfarin (53%)53% related to the paper
View PDF
369 Citations
open accessOpen access Journal Article DOI: 10.1177/107602960300900301
Platelets as predictors of vascular risk: is there a practical index of platelet activity?
Stavroula Tsiara1, Moses Elisaf2, I. Anita Jagroop1, Dimitri P. Mikhailidis1

Abstract:

Activated platelets play a role in the pathogenesis of coronary heart disease (CHD). Following activation, platelets change shape, aggregate, and release several bioactive substances. The aim of this review is to identify if there is a simple and cost-effective method that indicates platelet activation and predicts the risk o... Activated platelets play a role in the pathogenesis of coronary heart disease (CHD). Following activation, platelets change shape, aggregate, and release several bioactive substances. The aim of this review is to identify if there is a simple and cost-effective method that indicates platelet activation and predicts the risk of CHD and vascular events. The rationale for identifying high-risk patients is to reduce their risk of vascular events by administering appropriate and effective antiplatelet treatment, like aspirin, clopidogrel, or combination regimens. Many laboratory tests estimating platelet activity have been described. Some are relatively simple, such as spontaneous or agonist-induced platelet aggregation. Other tests include measuring the mean platelet volume (MPV) or plasma soluble P-selectin levels. Some more complex tests include flow cytometry to determine platelet GP IIb/IIIa receptors, platelet surface P-selectin, platelet-monocyte aggregates, and microparticles. Only few prospective studies assessed the predictive value of platelet activation in healthy individuals. Although the MPV seems an 'easy' method, there are insufficient data supporting its ability to predict the risk of a vascular event in healthy adults. Platelet aggregation, in whole blood or in platelet-rich plasma was not consistently predictive of vascular risk. Soluble P-selectin measurement is a promising method but it needs further evaluation. Flow cytometry methods are costly, time-consuming, and need specialized equipment. Thus, they are unlikely to be useful in estimating the risk in large numbers of patients. There is as yet no ideal test for the detection of platelet activation. Each currently available test has merits and disadvantages. Simple methods such as the MPV and the determination of platelet release products need further evaluation. read more read less

Topics:

Platelet aggregation inhibitor (72%)72% related to the paper, Platelet activation (72%)72% related to the paper, Mean platelet volume (70%)70% related to the paper, Clopidogrel (54%)54% related to the paper, Platelet (53%)53% related to the paper
322 Citations
Journal Article DOI: 10.1177/1076029609343004
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Joachim Stangier1, Andreas Clemens

Abstract:

Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor that is rapidly absorbed and converted to its active form, dabigatran. Dabigatran has been shown to be a potent, competitive, and reversible inhibitor of thrombin, inhibiting both thrombin activity and generation. Studies in healthy volunteers and in p... Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor that is rapidly absorbed and converted to its active form, dabigatran. Dabigatran has been shown to be a potent, competitive, and reversible inhibitor of thrombin, inhibiting both thrombin activity and generation. Studies in healthy volunteers and in patients undergoing orthopedic surgery indicate that dabigatran has a predictable pharmacokinetic profile, allowing for a fixed-dose regimen without the need for coagulation monitoring. In healthy volunteers, peak plasma concentrations of dabigatran are reached approximately 2 hours after oral administration. The elimination half-life is 12 to 14 hours, with clearance predominantly occurring via renal excretion of unchanged drug. Dabigatran is not metabolized by cytochrome P450 isoenzymes, has no interactions with food, and also has a low potential for drug-drug interactions. The pharmacokinetic profile of dabigatran is consistent across a broad range of different patient populations and is unaffected by gender, body weight, ethnic origin, obesity, and mild-to-moderate hepatic impairment. Small differences in dabigatran pharmacokinetics associated with age are attributable to variation in renal function. Dabigatran etexilate produces a predictable pharmacodynamic effect and requires no coagulation monitoring. It has been approved in the European Union (EU) and Canada for prophylaxis of thromboembolism in patients undergoing total knee or hip arthroplasty. Ongoing clinical trials are investigating its use in the treatment of venous thromboembolism, prevention of stroke in patients with nonvalvular atrial fibrillation, and treatment of thromboembolic complications, following acute coronary syndromes. read more read less

Topics:

Dabigatran (66%)66% related to the paper, Direct thrombin inhibitor (58%)58% related to the paper, European union (52%)52% related to the paper
View PDF
316 Citations
open accessOpen access Journal Article DOI: 10.1177/1076029620938149
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
Wolfgang Miesbach, Michael Makris1, Michael Makris2

Abstract:

The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2 and is characterized by an exaggerated inflammatory response that can lead to severe manifestations such as adult respiratory syndrome, sepsis, coagulopathy, and death in a proportion of patients. Among other factors and direct viral effect... The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2 and is characterized by an exaggerated inflammatory response that can lead to severe manifestations such as adult respiratory syndrome, sepsis, coagulopathy, and death in a proportion of patients. Among other factors and direct viral effects, the increase in the vasoconstrictor angiotensin II, the decrease in the vasodilator angiotensin, and the sepsis-induced release of cytokines can trigger a coagulopathy in COVID-19. A coagulopathy has been reported in up to 50% of patients with severe COVID-19 manifestations. An increase in d-dimer is the most significant change in coagulation parameters in severe COVID-19 patients, and progressively increasing values can be used as a prognostic parameter indicating a worse outcome. Limited data suggest a high incidence of deep vein thrombosis and pulmonary embolism in up to 40% of patients, despite the use of a standard dose of low-molecular-weight heparin (LMWH) in most cases. In addition, pulmonary microvascular thrombosis has been reported and may play a role in progressive lung failure. Prophylactic LMWH has been recommended by the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology (ASH), but the best effective dosage is uncertain. Adapted to the individual risk of thrombosis and the d-dimer value, higher doses can be considered, especially since bleeding events in COVID-19 are rare. Besides the anticoagulant effect of LMWH, nonanticoagulant properties such as the reduction in interleukin 6 release have been shown to improve the complex picture of coagulopathy in patients with COVID-19. read more read less

Topics:

Coagulopathy (60%)60% related to the paper, Disseminated intravascular coagulation (57%)57% related to the paper, Angiotensin II (56%)56% related to the paper, Thrombophilia (54%)54% related to the paper, Thrombosis (54%)54% related to the paper
View PDF
291 Citations
open accessOpen access Journal Article DOI: 10.1177/1076029615569568
The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio.

Abstract:

Inflammation plays an important role in the pathophysiology of vascular disease. In this review, we consider the associations between the neutrophil-lymphocyte ratio (NLR; an indicator of inflammation) and vascular disease and its associated risk factors. The NLR has received attention due to its role as an independent progno... Inflammation plays an important role in the pathophysiology of vascular disease. In this review, we consider the associations between the neutrophil-lymphocyte ratio (NLR; an indicator of inflammation) and vascular disease and its associated risk factors. The NLR has received attention due to its role as an independent prognostic factor for coronary artery disease. The NLR can also be affected by atherosclerotic risk factors, such as hypercholesterolemia, metabolic syndrome, diabetes, and hypertension. Importantly, it can predict mortality in cardiovascular diseases. There are also reports of a positive correlation between the NLR and commonly used inflammatory markers. Inflammation is important not only in pathophysiology but also clinical outcomes of many diseases. The NLR is a widely available, easily derived, and reproducible marker of inflammation. Unlike many other inflammatory markers, the NLR is inexpensive and readily available and it provides additional risk stratification beyond conventional risk scores. read more read less

Topics:

Metabolic syndrome (52%)52% related to the paper, Vascular disease (51%)51% related to the paper, Coronary artery disease (51%)51% related to the paper
View PDF
283 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Clinical and Applied Thrombosis/Hemostasis.

It automatically formats your research paper to SAGE formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Clinical and Applied Thrombosis/Hemostasis format uses SageV citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Clinical and Applied Thrombosis/Hemostasis in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Clinical and Applied Thrombosis/Hemostasis guidelines and auto format it.

2. Do you follow the Clinical and Applied Thrombosis/Hemostasis guidelines?

Yes, the template is compliant with the Clinical and Applied Thrombosis/Hemostasis guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Clinical and Applied Thrombosis/Hemostasis?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Clinical and Applied Thrombosis/Hemostasis citation style.

4. Can I use the Clinical and Applied Thrombosis/Hemostasis templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Clinical and Applied Thrombosis/Hemostasis.

5. Can I use a manuscript in Clinical and Applied Thrombosis/Hemostasis that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Clinical and Applied Thrombosis/Hemostasis that you can download at the end.

6. How long does it usually take you to format my papers in Clinical and Applied Thrombosis/Hemostasis?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Clinical and Applied Thrombosis/Hemostasis.

7. Where can I find the template for the Clinical and Applied Thrombosis/Hemostasis?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Clinical and Applied Thrombosis/Hemostasis's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Clinical and Applied Thrombosis/Hemostasis's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Clinical and Applied Thrombosis/Hemostasis an online tool or is there a desktop version?

SciSpace's Clinical and Applied Thrombosis/Hemostasis is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Clinical and Applied Thrombosis/Hemostasis?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Clinical and Applied Thrombosis/Hemostasis?”

11. What is the output that I would get after using Clinical and Applied Thrombosis/Hemostasis?

After writing your paper autoformatting in Clinical and Applied Thrombosis/Hemostasis, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Clinical and Applied Thrombosis/Hemostasis's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Clinical and Applied Thrombosis/Hemostasis?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Clinical and Applied Thrombosis/Hemostasis. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Clinical and Applied Thrombosis/Hemostasis?

The 5 most common citation types in order of usage for Clinical and Applied Thrombosis/Hemostasis are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Clinical and Applied Thrombosis/Hemostasis?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Clinical and Applied Thrombosis/Hemostasis's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Clinical and Applied Thrombosis/Hemostasis in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Clinical and Applied Thrombosis/Hemostasis Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Clinical and Applied Thrombosis/Hemostasis formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template